| Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ... The lancet oncology 17 (9), 1283-1294, 2016 | 994 | 2016 |
| CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma R Advani, I Flinn, L Popplewell, A Forero, NL Bartlett, N Ghosh, J Kline, ... New England Journal of Medicine 379 (18), 1711-1721, 2018 | 934 | 2018 |
| Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm … P Armand, A Engert, A Younes, M Fanale, A Santoro, PL Zinzani, ... Journal of Clinical Oncology 36 (14), 1428, 2018 | 694 | 2018 |
| COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ... The Lancet Oncology 21 (10), 1309-1316, 2020 | 612 | 2020 |
| Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma MGM Roemer, RA Redd, FZ Cader, CJ Pak, S Abdelrahman, J Ouyang, ... Journal of Clinical Oncology 36 (10), 942, 2018 | 310 | 2018 |
| Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma A Noy, S De Vos, C Thieblemont, P Martin, CR Flowers, F Morschhauser, ... Blood, The Journal of the American Society of Hematology 129 (16), 2224-2232, 2017 | 296 | 2017 |
| Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial A Davies, TE Cummin, S Barrans, T Maishman, C Mamot, U Novak, ... The Lancet Oncology 20 (5), 649-662, 2019 | 254 | 2019 |
| COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) L Pagano, J Salmanton-García, F Marchesi, A Busca, P Corradini, ... Journal of hematology & oncology 14 (1), 168, 2021 | 248 | 2021 |
| Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety W Hiddemann, AM Barbui, MA Canales, PK Cannell, GP Collins, J Dürig, ... Journal of Clinical Oncology, 2395-2404, 2018 | 220 | 2018 |
| The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients JJ Scarisbrick, P Quaglino, HM Prince, E Papadavid, E Hodak, M Bagot, ... British Journal of Dermatology 181 (2), 350-357, 2019 | 173 | 2019 |
| Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre RJ Haynes, S Read, GP Collins, SC Darby, CG Winearls Nephrology Dialysis Transplantation 25 (2), 419-426, 2010 | 149 | 2010 |
| Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial J Trotman, SF Barrington, D Belada, M Meignan, R MacEwan, C Owen, ... The Lancet Oncology 19 (11), 1530-1542, 2018 | 125 | 2018 |
| Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy TA Eyre, HS Walter, S Iyengar, G Follows, M Cross, CP Fox, A Hodson, ... Haematologica 104 (2), e68, 2019 | 123 | 2019 |
| Care of haematology patients in a COVID‐19 epidemic J Willan, AJ King, S Hayes, GP Collins, A Peniket British journal of haematology 189 (2), 241, 2020 | 101 | 2020 |
| Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis A Noy, S de Vos, M Coleman, P Martin, CR Flowers, C Thieblemont, ... Blood Advances 4 (22), 5773-5784, 2020 | 78 | 2020 |
| Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma SH Lim, N Campbell, M Johnson, D Joseph-Pietras, GP Collins, ... The Lancet Haematology 8 (8), e542-e544, 2021 | 77 | 2021 |
| CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial M Gleeson, C Peckitt, YM To, L Edwards, J Oates, A Wotherspoon, ... The Lancet Haematology 5 (5), e190-e200, 2018 | 71 | 2018 |
| A national service for delivering CD19 CAR‐T in large B‐cell lymphoma–The UK real‐world experience A Kuhnl, C Roddie, AA Kirkwood, E Tholouli, T Menne, A Patel, C Besley, ... British Journal of Haematology 198 (3), 492-502, 2022 | 66 | 2022 |
| Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom S Rule, GP Collins, K Samanta Journal of medical economics 17 (7), 459-468, 2014 | 66 | 2014 |
| NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome TA Eyre, R Clifford, A Bloor, L Boyle, C Roberts, M Cabes, GP Collins, ... British journal of haematology 175 (1), 43-54, 2016 | 65 | 2016 |
